Benefits
Sustained energy without spike or crash
zümXR ER delivers caffeine gradually over 6+ hours — not more than 55% at 1 hour and not less than 80% at 6 hours per specification. Compared to immediate-release caffeine (100% delivered within 1 hour), zümXR avoids the spike-and-crash cycle. Cmax (peak blood level) is approximately 50% of IR caffeine — empirically supporting the no-jitters positioning.
Avoidance of caffeine jitters and anxiety
The lower peak blood concentration (Cmax) of zümXR ER vs IR caffeine empirically supports its no-jitters positioning. Immediate-release caffeine spikes can produce anxiety, restlessness, and cardiovascular discomfort in sensitive individuals. zümXR's lower peak with extended duration produces the cognitive and performance benefits without these side effects — opening caffeine use to stimulant-sensitive populations.
Delayed Release for timed surge
zümXR Delayed Release uses a pH-activated coating that releases caffeine when the formulation passes from the stomach to the small intestine — providing an immediate surge at a fixed time delay (2 hours rather than the immediate 30-60 minutes of IR caffeine). Delivers not more than 25% at 1 hour and over 80% at 2 hours. Useful for delayed-onset energy needs (workouts started after meal).
Liquid-Stable form for beverages
zümXR Extended Release Liquid Stable Caffeine uses a non-pH-dependent lipid-based coating with enzymatic release. The innovation solves the long-standing problem of formulating extended-release caffeine in beverages — water-based formulations typically dissolve coatings prematurely. Opens beverage shots, RTDs, and functional drinks to controlled-release caffeine.
Custom energy profile design
Brands can combine immediate-release caffeine with either or both zümXR Extended Release and Delayed Release to design custom energy profiles tailored to the product use occasion. Examples: pre-workout with IR + ER for immediate boost + sustained workout energy; afternoon energy drink with IR + DR for quick start + afternoon slump prevention.
Validated with sleep-deprivation clinical trial
ClinicalTrials.gov NCT06441695 — a completed acute effects study by Applied Science & Performance Institute evaluating zümXR ER specifically following a night of suboptimal sleep. The real-world trial design (post-sleep deprivation) tests caffeine in its primary use case. Trial ran 2024-2025 with results pending publication.
COA-validated dissolution profile per batch
PLT Health ensures consistent performance by including tested dissolution results on the Certificate of Analysis (COA) for each lot. Very few competitors guarantee pharmacokinetic curve and dissolution profile of every batch — most provide unvalidated specifications. The COA-guaranteed quality is a significant advantage for brands and manufacturers seeking consistency.
Broad format flexibility
zümXR technology is suitable for a broad array of products: supplements (capsules, tablets), stick packs, powders, gummies, bars, gels, and (with Liquid-Stable) beverages. Featured in products including 9 Volt Pre-Workout (Like a Pro Supplements) and Body Fortress Elite Laser Start Pre-Workout. Modern format diversity addresses contemporary consumer delivery preferences.
Mechanism of action
Semi-permeable matrix extended release
zümXR ER uses a semi-permeable matrix that controls caffeine release independent of pH changes throughout the GI tract. Water slowly diffuses into the matrix, dissolves the caffeine, and allows it to diffuse out at a controlled rate. The pH-independence ensures consistent release regardless of stomach acid variation, food intake timing, or individual GI differences.
pH-activated delayed release
zümXR DR uses a pH-sensitive coating that remains intact in the acidic stomach (pH 1.5-3.5) but dissolves rapidly in the alkaline small intestine (pH 6-7.5). Once the formulation passes through the pyloric sphincter, the coating dissolves and provides a concentrated caffeine surge. Mechanism allows precise timing — approximately 2 hours after ingestion.
Lipid-based enzymatic liquid release
zümXR Liquid Stable uses a lipid-based coating that's stable in aqueous beverage environments but dissolves via enzymatic processes in the digestive tract. The pancreatic lipase and other digestive enzymes break down the lipid coating, releasing caffeine in a controlled manner. Mechanism enables beverages with sustained-release caffeine technology.
Standard caffeine adenosine antagonism
Once released, zümXR caffeine acts through standard caffeine mechanisms — primarily adenosine receptor antagonism. Caffeine blocks adenosine receptors that normally signal tiredness, reducing perceived fatigue. Also stimulates dopamine and norepinephrine pathways for mood and alertness. The release technology controls when caffeine acts — not how.
Reduced Cmax for tolerability
Slower release produces a lower peak blood concentration (Cmax) while extending total exposure (AUC remains similar). The lower peak directly translates to reduced side effects — jitters, anxiety, and cardiovascular effects scale with peak concentration rather than total exposure. Mechanism explains the empirical tolerability advantage of zümXR over IR caffeine.
Clinical trials
Pharmacokinetic comparison study evaluating zümXR Extended Release caffeine vs immediate-release caffeine. Blood caffeine concentration measurements at multiple timepoints over 6+ hours. Established the fundamental release profile that distinguishes zümXR from standard caffeine.
Healthy adults — pharmacokinetic study design with multiple blood sample timepoints.
IR caffeine delivered 100% of administered caffeine within 1 hour. zümXR-ER delivered just 26% at the 1-hour mark, yet 79% at the 6-hour mark. zümXR-ER Cmax was approximately 50% of IR caffeine's Cmax — empirically demonstrating reduced spike and avoidance of uncomfortable caffeine effects. Established the pharmacokinetic foundation for the no-jitters positioning.
Clinical trial NCT06441695 — 'The Acute Effects of PLT Health Solutions zümXR Extended-Release Caffeine on Side Effects, Mood and Alertness Following a Night of Suboptimal Sleep.' Conducted by Applied Science & Performance Institute. Real-world relevant test of caffeine in primary use case.
Adults following a night of suboptimal sleep. Acute effects design.
Completed October 2024. Investigated side effects, mood, and alertness following suboptimal sleep — caffeine's primary use case. Trial results expected to confirm the pharmacokinetic advantages translate to real-world tolerability benefits. The acute effects design captures meaningful daily-life outcomes vs prolonged chronic-use trials.
Extensive class evidence for caffeine's effects on alertness, cognitive performance, physical performance, and metabolic effects across hundreds of clinical trials. Caffeine is among the most-studied performance and cognitive substances. zümXR delivers caffeine with controlled pharmacokinetics — modulating timing and peak rather than the substance itself.
Various — adults across hundreds of caffeine trials in healthy, athletic, occupational, and clinical populations.
Caffeine consistently improves alertness, cognitive performance, endurance exercise capacity, and reduces perceived exertion. Effective doses 50-400 mg. Diminishing returns and increasing side effects above 300 mg single dose. The extensive class evidence supports zümXR applications — the technology provides standard caffeine benefits with improved tolerability profile.